Leqembi Trials Aren’t Over; Joining Could Save $26,500 Per Year
Interested in Leqembi? Clinical trials are still ongoing, and participants have a 50/50 chance of receiving the $26,500-per-year drug for free. Eisai and Biogen’s…
Interested in Leqembi? Clinical trials are still ongoing, and participants have a 50/50 chance of receiving the $26,500-per-year drug for free. Eisai and Biogen’s…
Certain medications and health factors could increase your risk of side effects when taking LEQEMBI™ and other monoclonal antibody drugs for Alzheimer’s. Here’s what…
Phil Gutis, a career reporter and writer living with early-onset Alzheimer’s, participated in the clinical trials for the first-ever disease-modifying Alzheimer’s drug. Now, he…
A new disease-modifying Alzheimer’s drug, lecanemab — which will be distributed under the brand name Leqembi — today secured FDA approval. Today, the Food…
Cuba has quietly been developing their own Alzheimer’s treatment. It’s administered nasally. And it’s just entered clinical trials. The United States imposed a blockade…
AmyriAD Therapeutics CEO Sharon L. Rogers shares the scoop on AmyriAD’s investigational Alzheimer’s drug AD101. The majority of experimental Alzheimer’s drugs are being designed…
New trial data presented at CTAD shows drug brexpiprazole is effective at treating agitation in people with Alzheimer’s dementia. The FDA may consider it…